secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2026-06-03T20:25:25+00:00
Accession:  0001213900-26-064744
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics CFO Matthew Szot leaves; CEO Quang Pham takes interim CFO role
--------------------------------------------------------------------------------

- CFO Matthew K. Szot mutually agreed to step down effective May 28, 2026.
- CEO Quang X. Pham appointed interim CFO and interim principal accounting officer.
- Company is conducting a search for a permanent CFO to replace Szot.
- Severance includes $365,806 severance, $237,903 FY2026 target bonus, and accelerated option vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026064744/0001213900-26-064744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026064744/ea0293458-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-064744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer